Fresenius Medical Care AG & Co. released its earnings report for the fourth quarter and full-year. FY2015 witnessed a decline in net income to $1.03 billion from the $1.05 billion of 2014. In line with this, the company posted earnings per share (EPS) of $3.38, down from the previous year’s EPS of $3.46.

Furthermore, Fresenius Medical Care’s full-year operating income tumbled 2% to $2.33 billion.

Excluding special items, however, Fresenius Medical Care had a net income of $1.09 billion, surging 2% from the previous year. Operating income also showed a 5% gain.

The company’s net revenue for the fiscal year was seen at $16.74 billion, signifying a 6% upsurge. Fresenius Medical Care met its guidance of 11% gain in revenue at a constant currency.

For the quarter, Fresenius Medical Care recorded a slight gain in net revenue of 1% or 5% at a constant currency compared to the same quarter last year. The company’s net revenue was seen at $4.35 billion.

Performance of Worldwide Segments for the Period

In North America, the fourth quarter revenue jumped 7% to $3.08 billion. International revenue, however, slipped 12%, bringing in a total of $1.26 billion.

Fresenius Medical Care’s segments in Europe, Middle East, and Africa (EMEA) had a revenue decline of 12% with a total of $673 million. Revenue in Asia-Pacific also slumped 6% to $394 million.

Operating income in North America and EMEA, on the other hand, climbed 4% and 20% respectively year-over-year. Meanwhile, operating income in Asia-Pacific lost 21%. Operating income came in at $514 million, $172 million, and $79 million for Fresenius Medical Care’s segments in North America, EMEA, and Asia-Pacific respectively.

2016 Revenue Guidance

Excluding some items from 2015 and 2016, Fresenius Medical Care gave a projection of 7% to 10% rise in revenue at a constant currency for the current fiscal year. Moreover, the company expects its net income attributable to investors to inch up 15% to 20% as well.

Dividend Increase

Fresenius Medical Care also increased its dividend to €0.80 from the previous €0.78 per share. The annual general meeting with investors will be held on May 12. This shows a 3% increase from 2014.